PDF(Pubmed)
Abstract：
The terms non-alcoholic fatty liver disease and non-alcoholic steatohepatitis have some limitations as they use exclusionary confounder terms and the use of potentially stigmatising language. Recently, a study with content experts and patients has been set to change this nomenclature. The term chosen to replace non-alcoholic fatty liver disease was metabolic dysfunction-associated steatotic liver disease (MASLD), which avoids stigmatising and helps improve awareness and patient identification. MASLD is the most common cause of chronic liver disease with an increasing prevalence, accounting for 25% of the global population. It is considered the hepatic manifestation of the metabolic syndrome with lifestyle playing a fundamental role in its physiopathology. Diet change and physical activity are the cornerstones of treatment, encompassing weight loss and healthier behaviours and a holistic approach. In Europe, there is no approved drug for MASLD to date and there is a substantial unmet medical need for effective treatments for patients with MASLD. This review not only provides an update on advances in evidence for nutrition and physical activity interventions but also explores the different therapeutic options that are being investigated and whose development focuses on the restitution of metabolic derangements and halting inflammatory and fibrogenic pathways.
摘要：
术语非酒精性脂肪性肝病和非酒精性脂肪性肝炎具有一些局限性，因为它们使用排他性混淆术语和使用潜在的污名化语言。最近,一项针对内容专家和患者的研究已经开始改变这个命名法。选择替代非酒精性脂肪性肝病的术语是代谢功能障碍相关的脂肪变性肝病（MASLD），这避免了污名化，并有助于提高意识和患者识别。MASLD是慢性肝病的最常见原因，患病率越来越高，占全球人口的25%。它被认为是代谢综合征的肝脏表现，生活方式在其病理生理学中起着重要作用。饮食改变和身体活动是治疗的基石，包括减肥和更健康的行为以及整体方法。在欧洲,迄今为止,还没有批准用于MASLD的药物,并且对于MASLD患者的有效治疗存在大量未满足的医学需求.这篇综述不仅提供了营养和身体活动干预证据的最新进展，而且还探讨了正在研究的不同治疗方案，其发展重点是恢复代谢紊乱和停止炎症和纤维化途径。
